1 / 75

Drug Intoxication and Withdrawal

Drug Intoxication and Withdrawal. Alexander Chyorny , MD November 2013. Pharmacological Treatment of Addiction. Neurotransmitters-101. Dopamine pathway – learning, pleasure Serotonin pathway – regulates mood Opioid pathway – antinociceptive Cannabinoid – appetite, pain, mood, memory

kalkin
Download Presentation

Drug Intoxication and Withdrawal

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Drug Intoxication and Withdrawal Alexander Chyorny, MD November 2013

  2. Pharmacological Treatment of Addiction

  3. Neurotransmitters-101 • Dopamine pathway – learning, pleasure • Serotonin pathway – regulates mood • Opioid pathway – antinociceptive • Cannabinoid – appetite, pain, mood, memory • Noradrenergic – alertness, decision-making • Cholinergic – memory, learning, arousal • Glutamate – excitation (NMDA, AMPA receptors) • GABA – inhibition

  4. Neural Reward Circuits Important in the Reinforcing Effects of Drugs of Abuse. Camí J, Farré M. N Engl J Med 2003;349:975-986.

  5. Brain Reward System:Mesocorticolimbic Dopamine Pathway modulates pleasure needed for survival: eating/drinking, sex, nurturing

  6. “The Substance” and the Brain:Neuroadaptation • Yin-Yang – homeostasis (activating/inhibiting) • Intoxication – temporary dominance • Tolerance – activating opposition, down-regulating receptors • Withdrawal – removing the drug; biological effects much longer-lasting (days to years) • Tx of WD – substance mimetics (long-acting, taper); antagonizing opposition

  7. Yin and Yang

  8. Drug craving Irritability Dysphoria Anxiety Insomnia + specific Sx of whatever agonist/antagonist receptor systems involved Immediate phase: starts w/i hours, lasts days Protracted phase: 6-18 mo (malaise, cravings)

  9. General Assessment Principles • Primary substance • type, route, frequency, amount, time of last use • Complications of use and withdrawal • History of medication-assisted detox • Concurrent substances use/co-morbidities • Vital signs • Mental status • Pupils • Ability to ambulate • Urine toxicology

  10. General Approach to O/D Coma cocktail • Thiamine 100 mg • 1 amp of D50 • Naloxone 2 mg

  11. Alcohol: the Most Common and Lethal • GABA-A vs. glutamate/NMDA • Indirect release of β-endorphins and dopamine • In and Out: consider Pruno, hand-sanitizers • Intoxication: slurred speech, confusion, ataxia, ↓HR; assess ability to protect airway • Withdrawal • Early symptoms 6-24 hrs • Seizures 12-48 hrs • Isolated hallucinosis 12-48 hrs • Delirium Tremens 48-96 hrs

  12. Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) • Most commonly used instrument, validated • Measures 10 subscales • Nausea/vomiting Tactile disturbances • Tremor Auditory disturbances • Diaphoresis Visual disturbances • Anxiety Headache • Agitation Orientation • Max score 67, prophylaxis if >8, hospitalization if >15-20, ICU if > 35

  13. EtOH: Cornerstones of Treatment • Monitor – CIWA-Ar, VS; close observation • EtOH substitutes – benzodiazepines • Supportive treatment • Quiet, protective environment • Correct hypovolemia/electrolytes • Thiamine (before glucose), MVI, folate, MgSO4 • Adjunct treatment • Beta-blockers, antipsychotics • Anticonvulsants • α2 agonists, muscle relaxants

  14. EtOH substitute: Benzodiazepines • Fixed ATC vs. Sx-triggered dosing • Chlordiazepoxide (Librium) • Longest-acting, active metabolites, auto-taper • 50-75 mg PO q 4-6 hrs, add’ldoses hourly prn • Lorazepam (Ativan) • Medium-to-short acting, no active metabolites • Preferable in patients with advanced cirrhosis or high risk for oversedation (elderly, co-morbidities) • 1-2 mg PO q 4-6 hrs, hourly prn

  15. EtOH Dependence • Medication is adjunct to ψ-social intervention • Acamprosate • NMDA partial antagonist; 666 mg tid • Disulfiram • Blocks alcohol dehydrogenase; nausea/flushing/↑HR; 250-500 mg/d • Naltrexone • Blocks μ-opioid receptors • Oral (50 mg/d) or injectable (380 mg/mo) • Baclofen • GABA-B agonist; anxiolytic; 10-20 mg tid • Topiramate • ↑GABA, ↓glutamate; slow titration to 300 mg/d

  16. Benzodiazepines • Most abused: short-acting alprazolam (Xanax) • Most common: clonazepam (Klonopin), Valium (Diazepam), lorazepam (Ativan) • Intoxication: similar to EtOH • WD: beware of much longer half-life • Tx: chlordiazepoxide or clonazepam taper • Carbamazepine as an alternative for w/d Sx

  17. Gamma-Hydroxybutyrate • Acts on specific GHB and GABA-B receptors • Euphoric, ↓inhibition, amnesia, hypotonia, somnolence, ↓HR, ↓BP, clonus, resp. depression • Short-acting; acute intoxication best treated with observation if no respiratory compromise • WD: similar to BZD/EtOH, less autonomic, more CNS – insomnia, tremor, anxiety; 1 wk • Tx: consider BZD taper, baclofen

  18. Z-drugs • Zolpidem, zaleplone, (es)zopiclone • GABA-A receptor; effects similar to BZD • High doses – euphoria, exaltation, anxiolysis • Dependence, withdrawal – similar to BZD (from sympathetic O/D to Sz) • Tx: consider diazepam or gabapentin taper

  19. Carisoprodol (Soma) • Metabolized into meprobamate • Acts on GABA-A; similar to barbiturates/BZD • Sedative, relaxant, euphoric; synergy w/ opiates • Abuse increasing; 2012 - schedule IV • WD: anxiety, insomnia, HA, myalgia, tremors, hallucinations, paranoia • Tx: consider BZD taper (if 12-25 tab/day)

  20. Gabapentin (Neurontin) • Increased availability of endogenous GABA, +/- action on GABA-B, ↓ glutamate release • Intranasal snorting: high similar to cocaine • Oral use: similar to EtOH, BZD • WD: depression, anxiety, insomnia, depersonalization, paresthesias, delirium • Tx: taper for doses >1800 mg/d

  21. Pregabalin (Lyrica) • Similar to gabapentin • Higher potency, quicker absorption, ↑ bioavailability • Euphoric, dissociative effects; tolerance • WD: agitation, tremor, ↑ HR, ↑ BP • Tx: 1-wk taper (for doses > 300 mg/d)

  22. Topiramate (Topamax) • Augments GABA action • Antagonizes AMPA/kainate glutamate receptor • Often requested for wt loss properties • Emerging usefulness in EtOH and stimulant dependence • Literature indicates little potential for abuse • SE – somnolence, memory problems, paresthesias

  23. Opiate Intoxication and Tolerance • Heroin: fine china vs. black tar • μ, δ, κ, σ receptors • Analgesia, modulation of respiration, miosis, gut motility; trigger DA release in nucleus accumbens - euphoria • Tolerance: receptor desensitization, AChdownregulation, cAMPupregulation

  24. Opiate Overdose • Heroin, morphine, oxycodone, hydrocodone, methadone • AMS, stupor, miosis • ↓BP, ↓HR, slow shallow breaths, pulmonary edema • Motionless in a cold environment: • ↓temp, rhabdomyolysis, renal failure • Meperidine (Demerol), propoxyphene (Darvon), tramadol (Ultram) – mydriasis, Sz • Assess responsiveness, airway protection • Look for fentanyl patches • Tx: naloxone (Narcan) 0.04-0.5-1-2-4-10 mg IV q 2 min • Watch out for concurrent acetaminophen O/D (Norco, Percocet)

  25. Opiate Withdrawal • Morphine, heroin – 6-12 hrs, methadone 36-48 hrs; last ≈ 2 wks • Activation of cholinergic and noradrenergic systems • Symptoms and signs – COWS • Nausea, diarrhea, cramping, lacrimation, rhinorrhea, diaphoresis, chills • Irritability, anxiety, insomnia, yawning, ↑HR, ↑BP • Opiate substitution • Methadone taper – daily, 20-30 d; most Sx at the end; few SE • Buprenorphine – few studies, varying doses/duration • Tramadol – limited literature, similar effectiveness to buprenorphine • α-2 agonists – modulate noradrenergic hyperactivity • Clonidine 0.1-0.3 mg tid x 2-4 days, taper over 7 days • Reduces WD Sx; increases # who completed WD (vs. placebo) • SE: drowsiness, dizziness, hypotension, dry mouth • Sxtx: acetaminophen, donnatal, loperamide, hydroxyzine, melatonin

  26. Tx of Opiate Dependence • Substitute therapy • Methadone; 60-100 mg/d; QTc monitoring • Buprenorphine; 8-24 mg/d • Pure (Subutex) or combo with naloxone (Suboxone) • Antagonist therapy • Oral naltrexone; 50 mg/d • Injectable naltrexone; 380 mg/d

  27. Stimulants

  28. Classic Stimulants Cocaine Amphetamines Speed/crack/crystal meth, Rx (Adderall, Dexedrine) Besides transporter inhibition, ↑DA, NE>serotonin release, MAOI Effects last hours Related stimulant: methylphenidate (Ritalin) • Hydrochloride salt vs. free-base (crack) • DA, NE, serotonin uptake transporter inhibition • Lasts 30-60 min • Beware of combos: “speedball”, cocoethylene Euphoria, ↑ libido, ↓ appetite, ↑ concentration Sleeplessness, anxiety, paranoia, aggression

  29. Classic Stimulants: Intoxication • Adrenergic stimulation (α,β), DA, serotonin (release, ↓re-uptake) • ↑BP, ↑HR, ↑temp, mydriasis • Dry mucous membranes and diaphoresis • Agitation, delirium, hypertonia, seizures • Vasospasm (myocardial, cerebral), arrhythmia • Rhabdomyolysis, renal/hepatic toxicity • Tx: lorazepam, haloperidol, labetalol for HTN; nitrates/CCB for chest pain; cooling

  30. Stimulant O/D: Tx Considerations • Avoid 3Ps • Physical restraints • Phenothiazines in escalating doses • Psychiatric ward • Use ART • Acceptance (explanation, reassurance) • Reduce stimuli (dark, quiet environment) • Talkdown

  31. Stimulant Withdrawal • Chronic use ↓ glutamate, DA, serotonin • WD (“tweaking”) w/i 24 hrs of last dose • “Crash” – acute, 1wk; subacute – 2-3 wks • Hyperarousal: craving, agitation, vivid dreams • Reversed vegetative: hypersomnia, ↓ energy, ↑appetite • Anxiety: dysphoria, anhedonia, paranoia, ψmotor slowing

  32. Tx of Stimulant WD and Dependence • No proven tx, but a number of research avenues • Modafinil: mild stimulant, ↑ glutamate; blocks euphoria • May attenuate cocaine w/d • Not effective for methamphetamine dependence • GABAergics for maintenance • Vigabatrin, topiramate • Disulfiram • Increases cocaine/DA levels, unpleasant anxiety • Cocaine and methamphetamine vaccines • Stimulate production of Ab which prevent stimulants’ entrance into CNS

  33. Ecstasy/MDMA • 3,4-methylenedioxymethamphetamine • Serotonin > DA/NE reuptake inhibition • Onset 30 min, last 4 hrs • Intense sensual experiences, empathy, sociability, insomnia, ↓appetite • ↑Temp, ↑BP, ↑HR, mydriasis, diaphoresis, trismus • Serotonin syndrome, hyponatremia, dehydration • No medications for tx of mild intoxication or WD • Dependence rare, largely psychological

  34. Bath Salts • Cathinone (Khat plant) derivatives, stimulants • Mephedrone, methylenedioxypyrovalerone • Mephedrone: more stimulant, onset/action 30-60 min • MDPV: more hallucinatory, onset 1 hr, lasts 2-3 hrs • DA, serotonin, NE reuptake inhibition • Euphoria, hallucinations → insomnia, paranoia • Agitation, twitches, ↑HR, ↑BP, ↑ temp, mydriasis, Sz • Rhabdomyolysis, renal failure, MI, excited delirium • WD: very severe cravings, fatigue, irritability; 1-2 d • Tx: cooling, hydration, lorazepam, haloperidol

  35. Albuterol • Stimulant-like (ᵦ-adrenergic) • Clenbuterol – pill, abused by body-builders • Frequent canister exchange – red flag • Spray on paper, dry, inhale powder • ↑HR, ↓BP, tremor, agitation • Tx: observation; consider propranolol

More Related